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Background
Histones are basic proteins and are modified by diverse
post-translation modifications such as acetylation,
methylation, phosphorylation and ubiquitinylation.
These epigenetic modifications are important regulatory
processes in proliferation, survival, differentiation and
motility. The epigenetic gene regulation occurs in DNA
methylation at DNA level and histone modification or
chromatin remodelling at protein level. Several enzymes,
like DNA methyltransferases (DNMTs), histone methyl-
transferases (HMTs), histone demethylases (HDMs), his-
tone acetyltransferases (HATs) and histone deacetylases
(HDACs), are able to modify the chromatin. The histone
modifications lead to alterations in chromatin and form
heterochromatin or euchromatin, which activates or
silences transcription. Statins are used successfully in
the treatment of hypercholesterolemia and inhibit 3-
hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase.
HMG-CoA reductase is the rate-limiting enzyme of the
mevalonate pathway. The synthesis of isoprenoids such
as farnesylpyrophosphate (FPP) and geranylgeranylpyro-
phosphate (GGPP) is reduced by statins by inhibition of
the HMG-CoA reductase. These isoprenoid intermedi-
ates are involved in post-translational modifications of
Ras, Rho and Rac, which are typical for G proteins and
have crucial roles in cancer cells.
Methods
Western blot analysis was performed to quantify acetyla-
tion status of histones in SH-SY5Y and RD cell lines.
Results
SH-SY5Y and RD cells were treated and incubated with
increasing concentrations of simvastatin. The lysates
were separated in a cytosolic and nuclear fraction.
acetylated proteins were detected mainly in the nuclear
fraction. Interestingly, the pattern of acetylation did not
change very much upon statin exposure in the cytosol.
However, in the nuclear fraction simvastatin extracts
were acetylated to a greater extent.
Conclusions
The data presented here suggest that simvastatin can
affect histones and their post-translational modifications.
Enhanced acetylation of nuclear proteins induced by sim-
vastatin might be interpreted as an inhibition of a HDAC
activity or/and as an increased HAT-mediated acetylation
in SH-SY5Y and RD cells.
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